Table 3.
Pharmacokinetic parameters of CyA in renal transplant patients on day 28 after transplantation
| All subjects | male | Female | ||
|---|---|---|---|---|
| (n=81) | (n=50) | (n=31) | ||
| Dose | (mg) | 296.0±65.0 | 311.5±65.3 | 269.4±53.9** |
| C0 | (ng/mL) | 245.1±88.4 | 251.1±97.7 | 235.4±73.1 |
| C2 | (ng/mL) | 1138.1±391.8 | 1060.4±398.9 | 1263.3±358.2* |
| Cmax | (ng/mL) | 1346.7±402.5 | 1319.7±437.9 | 1390.2±339.9 |
| Tmax | (hr) | 2.38±0.93 | 2.50±1.02 | 2.19±0.75 |
| t1/2 | (hr) | 3.30±1.06 | 3.43±1.24 | 3.08±0.64 |
| MRT | (hr) | 5.60±1.50 | 5.82±1.78 | 5.25±0.75 |
| CLtot(app,abs) | (L/hr) | 41.81±13.6 | 45.0±15.6 | 36.7±7.6** |
| Vdss(app,abs) | (L) | 228.6±74.8 | 251.1±80.0 | 192.4±49.5** |
| AUC0-9 | (hr·ng/mL) | 6132.7±1494.1 | 5980.9±1559.9 | 6316.0±1341.8 |
C0, whole blood concentration at predose; C2, whole blood concentration at 2-hour postdose; Cmax, maximum whole blood concentration; Tmax, time when CyA concentration reached Cmax; t1/2, terminal elimination half-life; MRT, mean residence time; CLtot(app,abs), absolute apparent total clearance; Vdss(app,abs), absolute apparent volume of distribution at steady state.
Each value represents the mean ± S.D.
*, p<0.01, **, p<0.01, significant difference against male.